Indication:General trauma, abrasions, post-surgical wounds / diabetes mellitus, pressure sores and other chronic wounds / first & second-degree burns / wounds caused by tumors or chemotherapy / wounds at the donor site and graft site / intubation site / full thickness & partial-thickness wounds
INDICATION: GENERAL TRauma, abrasions, post-surgical wounds / diabetes mellitus, pressure sores and other chronic wounds / first & second-degree burns / wounds caused by tumors or chemotherapy / wounds at the donor site and graft site / intubation site / full thickness & partial-thickness wounds
KoCarbonAg Antimicrobial Silver Carbon Wound Dressing is a new generation silver activated carbon fiber dressing clinically proven to provide antimicrobial effect.
KoCarbonAg Antimicrobial Silver Carbon Wound Dressing™ is designed for infectious acute/chronic wounds and difficult wounds. The lining (wound contact layer) of KoCarbonAg® Antimicrobial Dressing™ is primarily composed of PET non-woven fabric, silver activated carbon fiber fabric and PE membrane. The Antimicrobial Dressing contains silver at a level of 0.1 mg/cm2. When in contact with the wound, the bandage will provide excellent absorption and moisturizing effect to absorb blood exudate and bacteria and provide a moist environment for the wound. The silver ions in the dressing can inhibit the growth of bacteria absorbed by the dressing from the wound, and form an antimicrobial barrier that prevents infection and reduces wound odor.
The activated carbon fiber in the KoCarbonAg® Antimicrobial Silver Carbon Wound Dressing™ can moisturize the wound. It creates a moist environment for the wound to recover and shortens healing time. The dressing can be cut into the size of the wound. The low adhesion wound contact layer can effectively reduce the adhesion with the wound and reduce the pain when changing the dressing.
1. Provides protection and kills all kinds of bacteria
It is indicated for infectious wounds and will not induce drug-resistance; relieves pain, improves wound healing and promotes epithelialization.
Provides 97.92% bactericidal effect on the multidrug-resistant Acinetobacter baumannii [AB bacterium] and 99.99% bactericidal effect on both drug-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa.
2. Microporous Structure
Absorbs bacteria and tissue exudate from the wound, and reduces wound odor.
3. Blocks ultraviolet radiation, and prevents pigmentation
4 Shortens wound healing time, and cuts down medical costs
5.Porous and moisturizing, and provides a moist environment for wound healing
6. Does not affect X-ray or MRI examination
- Partial and full thickness wounds
- Pressure ulcers
- Diabetic ulcers
- Surgical wounds
- Acute wounds (1st and 2nd degree burns)
- To avoid adhesion at the wound, do not use the dressing with oil-based medicinal liquor.
- This product is unsuitable for individuals allergic to carbon fiber and silver.
- If the package is broken or the dressing structure separates into several layers before use, please contact the customer service. Do not use it.
- Pregnant women and newborns must follow the doctor’s instruction for use.
- This product contains silver ions that provide excellent antimicrobial effect and can effectively inhibit inflammatory response. However, please do not replace systemic treatment or other appropriate medical procedures of infection treatment with this product.
- If black powders are found in the package or near the wound when changing the dressing (the black powders can be cleaned with normal saline), please do not worry as this is normal for activated carbon fiber.
- It is normal to feel tingling when using the bandage.
- It is advised to change the bandage based on the condition of the exudation. To avoid risk of infection, do not re-use the product.
- This product is for external use only.
- If redness, swelling, pain, or burning sensation occurs near the wound after use, please stop using the product and consult medical professionals.
- If PE membrane detaches from the bandage when changing the dressing, the dressing has absorbed too much exudate. It does not implicate a defect in the product. Please do not re-use the bandage.
- For third-degree burns, infectious wounds, wounds with exposed bones or tendons, or other conditions beyond the scope indicated by the original product design, please consult medical professionals to assess whether the product is appropriate for use in these wounds.
- After using the product in accordance with standard wound handling procedure, please consult medical professionals to re-assess the treatment plan if the wound appears abnormal.
- After use, please place the used product in the bag and dispose of it in non-recycle bin. Do not dispose of it carelessly.
Directions For Use
Please follow the instructions recommended by medical professionals.
- Please clean or shave the hair surrounding the wound depending on its condition in order to apply the dressing.
- Clean the wound with normal saline.
- Wipe and dry the skin around the wound.
Cover the wound
- Choose the size of the dressing that completely covers the wound (the dressing should have a diameter preferably 2~3 cm larger than the wound).
- With the black side facing the wound, apply the dressing to the wound.
- Use permeable tape or suitable bandage to secure the dressing to the appropriate location.
- For heavy exudate, use an extra layer of gauze on top of the dressing.
- Lift the dressing gently by the four corners and remove it from the wound.
- If adhesion forms at the wound, please rinse the wound with proper amount of normal saline.
- When 80% of the dressing is saturated with exudates from the wound, please change the dressing in accordance with the method described above.
MPs have scrutinized the Department of Health and the NHS in England for being “too moderate” to act in forestalling and treating diabetes.
A report by the Public Accounts Committee says varieties being taken care of by both sort 1 and 2 diabetes mean the yearly cost to the wellbeing administration will keep on rising.
For individuals matured 16 and over the bill as of now stands at £5.5bn a year.
A NHS England representative said “diabetes care [was] beyond anyone’s imagination”.
In any case, he additionally said the heftiness fuelled hop in sort 2 diabetes debilitated to “overpower GP administrations”.
“…[It] puts the spotlight solidly on the requirement for no nonsense national activity on counteractive action by the NHS, government, managers, schools, and specifically the nourishment business,” he included.
‘Not keeping pace’
The panel said the quantity of grown-ups in England with diabetes has ascended to more than 3 million, and was going up by very nearly 5% consistently.
The quantity of individuals with diabetes is expanding, similar to the quantity of patients who create complexities
Meg Hillier, Chairwoman of the Public Accounts Committee
The legislature and NHS England had depicted an “unduly solid picture” of the condition of diabetes administrations, it included.
The vast majority of the £5.5bn-a-year expense is spent on inconveniences from diabetes, for example, heart and kidney infection, visual deficiency and nerve harm, prompting removals.
These can be minimized by coming down with the sickness early, and overseeing blood glucose, circulatory strain and cholesterol.
Yet, the board of trustees said that part of the issue arrived were “inadmissible varieties” in training, consideration and treatment of patients.
In addition, just 60% of patients get the yearly checks prescribed to keep them sound and avert long haul intricacies.
The report additionally said diabetes authority staffing levels in healing facilities “are not keeping pace” with the expanding rate of beds possessed by diabetes patients.
‘Targets not met’
It said: “The rate of beds in intense healing centers in England involved by individuals with diabetes keeps on ascending, from 14.8% in 2010 to 15.7% in 2013.
“Be that as it may, the level of diabetic authorities has not fundamentally changed over this period. In 2013, almost 33% of healing facilities in England participating in the review had no diabetes inpatient pro medical attendant and 6% did not have any expert time for diabetes inpatient care.
“NHS England let us know that an expansion in nursing numbers isn’t likely in the following year or two.”
Meg Hillier, executive of the board of trustees, said: “The NHS and Department for Health have been too moderate in handling diabetes, both in counteractive action and treatment.
“The quantity of individuals with diabetes is expanding, similar to the quantity of patients who create entanglements. It is an intense condition that can hugy affect individuals’ lives.”
She said citizens must have certainty that backing is accessible when and where they require it, “as opposed to by ethicalness of where they live”.
What is diabetes?
An unending illness, which happens when the pancreas does not create enough of the hormone insulin, or when the body can’t adequately utilize the insulin it produces
This prompts an expanded convergence of glucose in the blood (hyperglycaemia)
TYPE 1 diabetes is described by an absence of insulin generation
TYPE 2 diabetes is created by the body’s incapable utilization of insulin, and regularly comes about because of abundance body weight and physical idle
Covalon Presenting Its Latest Advanced Wound Care and Infection Control Products at Arab Health 2016
MISSISSAUGA, ON, Jan. 21, 2016 /CNW/ – Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV), an advanced medical technologies company, today announced it is presenting its latest line of advanced wound care and healthcare acquired infection control products from January 25th-28th at the Annual Arab Health Congress in Dubai, U.A.E. Arab Health provides an opportunity for Covalon to meet the 65,000 medical and scientific community attendees, medical product manufacturers, wholesalers and distributors from the Middle East, Asia, Europe, North America and most other regions of the world.
Covalon will be showcasing its category transforming products at Arab Health, including SurgiClear™ and IV Clear™ – breathable, clear, dual antimicrobial silicone adhesive surgical wound and vascular access securement dressings, as well as ColActive Plus Ag, a patented BioMatrix wound dressing available for use in most Middle Eastern jurisdictions.
“With this being our 5th year at the Arab Health Congress, we have shown not only our commitment to launching innovations into the region, but the region has shown us in return its willingness to be leaders in the adoption of new medical technologies that address its biggest healthcare challenges.” said John Hands, Covalon’s Senior Director of Global Marketing. “After rigorous evaluations by leading physicians and clinicians in Saudi Arabia, Qatar, Kuwait, UAE, Bahrain, Oman and other countries, our products have been successful in winning business in no less than 14 tenders this past year alone. Covalon and our brands are becoming market leaders in the Middle East as a result of the hard work of our partners in the region, like Cure Development International Ltd.”
“We are pleased to represent Covalon and their portfolio of world-class products in the Gulf Cooperation Council (“GCC”) countries”, said Azzam Al Sulaim, Cure Development International, Ltd.’s Chief Executive Officer. “The combination of our highly experienced clinical sales experts and Covalon’s life-saving products is providing needed advanced wound care, infection control and surgical dressing solutions to the GCC that are having a positive impact on clinicians and their patients. We look forward to introducing more of Covalon’s products to the GCC as they become available.”
MADURAI: A Diabetic Education and Prevention study conducted on workers in Tuticorin shows that there is prevalence of diabetes among 23% of the organized and unorganized workers and, of the total sample, only 30 per cent of the workers have knowledge of relevant and verified information regarding the disease.
The study tested the level of awareness that the workers had about diabetes mellitus and how correct the information they possessed was. It was based on pre-tested interview schedule; parameters such as level of information possessed, perception of risk, prevalence of diabetes, myths and misconceptions that prevail about diabetes and other general factors such as food intake, health status, etc., were tested.
The results from this study show that diabetes is prevalent amongst 23 per cent of the workers while 10 per cent are at risk and in pre-diabetic stages. Among the diabetic, only 21 per cent regularly exercise and only 32 per cent of them take regular treatment for it. Seven per cent of the diabetic workers have never even considered any treatment for their disease. Fifty eight per cent of the patients say allopathic treatment is better for diabetes. Of the entire sample, only 30 per cent had correct information regarding what diabetes is and its effects. Ignorance about the disease is such that 74 per cent of the diabetic population consumes rice thrice a day. The study has brought to light the ubiquitous ignorance about a disease as prevalent as diabetes mellitus and the importance of educating the people about it.
The 2.3% Medical device tax is now suspended for two years. The suspension was approved and passed with the latest budget debate on Capitol Hill. The medical device tax was implemented to help pay for some of the expenses of the Affordable Care Act passed when the democrats had the majority in the executive, senate and congress. The $1.8 billion tax was not popular in the medical device industry. For example, Medtronic was expected to pay $210 million for 2016